Bay Area Cancer Research Group

Concord, California 94520

0 studies enrolling now · 15 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chronic Lymphocytic Leukemia, Diarrhea, Iron Overload, Metastases, Metastases, Neoplasm, Metastasis, Multiple Myeloma, Myelodysplastic Syndrome

Studies at this site

• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients — Completed
• AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer — Completed
• A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma — Completed
• SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) — Completed
• Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome — Stopped early
• Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC — Completed
• Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer — Completed
• A Multiple Myeloma Trial in Patients With Bone Metastases — Completed
• Non-small Cell Lung Cancer Registry — Completed
• STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea — Completed
• A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) — Completed
• Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Completed
• Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma — Completed
• Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. — Status unconfirmed
• An Investigational Drug (CAL) Versus Zoledronic Acid (Zometa®) in Patients With Breast Cancer — Completed